Shin Nippon Biomedical Laboratories Full Year 2025 Earnings: EPS Beats Expectations

Simply Wall St

May 10, 2025

Shin Nippon Biomedical Laboratories (TSE:2395) Full Year 2025 Results

Key Financial Results

Revenue: JP¥32.4b (up 23% from FY 2024).
Net income: JP¥4.92b (down 11% from FY 2024).
Profit margin: 15% (down from 21% in FY 2024). The decrease in margin was driven by higher expenses.
EPS: JP¥118 (down from JP¥133 in FY 2024).

Our free stock report includes 3 warning signs investors should be aware of before investing in Shin Nippon Biomedical Laboratories. Read for free now.

earnings-and-revenue-growth — TSE:2395 Earnings and Revenue Growth May 10th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shin Nippon Biomedical Laboratories EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 7.2%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia.

Performance of the market in Japan.

The company's shares are down 13% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Shin Nippon Biomedical Laboratories (at least 1 which can't be ignored), and understanding them should be part of your investment process.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.